Quantitative targeted proteomics for occult cancer screening in patients with unprovoked venous thromboembolism: results from the prospective PLATO-VTE study.

ABSTRACT:

Background

About 5% of patients with unprovoked venous thromboembolism (VTE) have occult cancer. Despite standard cancer screening, 50% of cancers remain undetected.

Objectives

We used quantitative targeted proteomics to identify novel cancer biomarkers among patients with unprovoked VTE.

Methods

Patients aged ≥40 years with a first unprovoked VTE and without a malignancy in the preceding 5 years were invited to an international prospective cohort study. Plasma samples were collected within 10 days after VTE. The primary outcome was an adjudicated cancer diagnosis during 12-month follow-up. Concentrations of 269 plasma proteins covering coagulation, complement, and cancer-associated pathways were measured using quantitative mass spectrometry-based targeted proteomics.

SUBMITTER: Guman NAM 

PROVIDER: S-EPMC12478244 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature